SAN FRANCISCO, Mar 03, 2010 (BUSINESS WIRE) -- Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty pharmaceutical
company focused on the development of treatments for urological
disorders and pain, announced today that Edward R. Teitel, MD, JD has
been elected Chairman of the Board of Directors.
"Dr. Teitel practiced surgery before becoming an attorney and an
entrepreneur," said Urigen's CEO William J. Garner, MD. "He brings
important clinical and legal expertise to Urigen at a critical time as
we work to advance URG101."
Edward R. Teitel, M.D., J.D., M.B.A. currently serves as the President
and Chief Executive Officer of ThromboVision, Inc. Prior to founding
ThromboVision in 2005, Dr. Teitel served as Senior Vice President and
Chief Medical Officer at MicroMed Technology, Inc. (now MicroMed
Cardiovascular, Inc.). As a part of senior management at MicroMed, Dr.
Teitel participated in all aspects of clinical trials and regulatory
matters, business scope and fund raising activities, as well as legal
matters. As chief medical officer for the DeBakey Left Ventricular
Assist Device at MicroMed, Dr. Teitel acquired extensive experience in
platelet function and anti-platelet therapy, especially relating to
artificial surface devices. Before joining MicroMed Technology in 2002,
Dr. Teitel practiced for many years as a board certified general and
vascular surgeon. He founded, managed, and developed a multi-specialty
group practice in Alabama until he closed his practice in 1997 to
transition into corporate medicine and management. Dr. Teitel earned his
MBA at Auburn University and worked with a boutique investment banking
firm, Colby Capital, in Atlanta where he worked to fund start-up
companies in the life sciences. After completing law school in 2002, he
joined the senior management team at MicroMed. Dr. Teitel earned his MD
degree at the University of Texas Health Science Center at San Antonio,
and completed his surgical residency at St. Joseph Mercy Medical
Hospital in Pontiac, Michigan. He received his Juris Doctor degree from
the University of Houston, with a focus in healthcare law, intellectual
property and business law. Dr. Teitel holds a BS in chemistry from Sul
Ross State University.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic
products for urological disorders. Urigen's two lead programs target
significant unmet medical needs and major market opportunities in
urology. Urigen's URG101, a proprietary combination of approved drugs
that is instilled into the bladder, targets painful bladder syndrome,
which affects approximately 10.5 million men and women in North America.
Urigen's URG301, a proprietary dosage form of an approved drug that is
locally delivered to control urinary urgency, targets acute urgency in
females diagnosed with an overactive bladder, another major unmet need
that is insufficiently managed by presently available overactive bladder
drugs. For further information, please visit Urigen's website at http://www.urigen.com.
This press release may contain forward-looking statements. These
statements may be identified by the use of forward-looking terminology
such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "plan," "potential," "predict,"
"should," or "will," or the negative thereof or other variations thereon
or comparable terminology. Urigen has based these forward-looking
statements on current expectations, assumptions, estimates and
projections. While Urigen believes that these expectations, assumptions,
estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and
uncertainties, many of which are beyond its control. Given these risks
and uncertainties, investors and security holders are cautioned not to
place undue reliance on such forward-looking statements. Urigen does not
undertake any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments.
SOURCE: Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc.
William J. Garner, MD, 415-781-0350
Chief Executive Officer